Sign In
Buy BIVI
$1.65
-0.0500 (-2.94%)
At Close: Jun 03, 2026
BioVie Announces Amended Terms for Asset Acquisition from Privately Held NeurMedix
08:19am, Monday, 10'th May 2021
SANTA MONICA, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for chronic debilitating liver
Insider Weekends: Director Of Selecta Biosciences Purchases Over Half A Million Dollars' Worth Of Stock
10:04am, Monday, 19'th Oct 2020
Insider buying decreased once again last week. Notable Insider Buys: Gossamer Bio, Inc., Selecta Biosciences, Inc., Citigroup Inc., Loop Industries, Inc., and BioVie Inc.
BioVie : Announces Closing of Public Offering of Common Stock | MarketScreener
12:02pm, Wednesday, 23'rd Sep 2020BioVie to Present at Oppenheimer Fall Healthcare Life Sciences & Medtech Summit | | IT Business Net
12:12pm, Monday, 21'st Sep 2020
SANTA MONICA, CA / ACCESSWIRE / September 21, 2020 / BioVie Inc. (NASDAQ:BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for liver dise
BioVie Inc. Announces Nasdaq Listing and Pricing of $15.7 Million Public Offering | | IT Business Net
12:11am, Friday, 18'th Sep 2020
SANTA MONICA, CA / ACCESSWIRE / September 17, 2020 / BioVie Inc. (NASDAQ:BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for liver dise
Fitness studios move classes outdoors to make up for revenue lost to the pandemic
03:00pm, Saturday, 25'th Jul 2020
Holding classes outdoors provides these outlets, among the last to gain authorization for reopening in many states, an alternative to less-profitable online offerings.
CORRECTING and REPLACING Carousel Group Enters U.S. Sports Betting Market Behind SportsBetting.com
12:00am, Thursday, 07'th May 2020
Carousel Group enters United States sports betting market to take on industry giants with a unique approach and flagship brand: SportsBetting.com.
OSI Pharmaceuticals Decision Has Limited Use in Supporting Patentability of Method of Treatment Claims
05:15pm, Wednesday, 04'th Dec 2019
Earlier this month, Mallinckrodt succeeded in its inter partes review (IPR) challenge against patent owner Biovie, Inc. Biovie attempted to use the recent Federal Circuit decision in OSI Pharmaceutica
